CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.02BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.03xvs all stocks
52-Week Change
92.79%vs all stocks
Market Capitalization
1.02BUSDvs all stocks (USD)
Enterprise Value
589.19MUSDvs all stocks (USD)
Forward P/E
-3.62xvs Biotechnology peers
Price to Book (MRQ)
2.35xvs Biotechnology peers
Enterprise to EBITDA
-2.22xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-32.44%vs Biotechnology peers
Return on Equity (TTM)
-67.47%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-265.10MUSDvs all stocks (USD)
Net Income (TTM)
-263.67MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-225.18MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-131.86MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
0.00USDFY2025 · Dec 31, 2025Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-244.83MUSDvs all stocks (USD)
Pre-tax Income
-229.71MUSDFY2025 · Dec 31, 2025Income Tax Expense
611.00KUSDFY2025 · Dec 31, 2025Net Income
-230.32MUSDFY2025 · Dec 31, 2025EBIT
-222.46MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-219.85MUSDFY2025 · Dec 31, 2025Research & Development
202.86MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
41.97MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
7.25MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.53USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.53USDFY2025 · Dec 31, 2025Basic Shares Outstanding
64.46MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
64.46MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-230.32MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
3.00MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-219.66MUSDFY2025 · Dec 31, 2025Free Cash Flow
-219.70MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
334.52MUSDFY2025 · Dec 31, 2025Interest Paid
5.06MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-230.32MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.62MUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.90MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-1.02MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-2.02MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.81MUSDFY2025 · Dec 31, 2025Capital Expenditures
-35.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-265.37MUSDFY2025 · Dec 31, 2025Sale of Investments
468.40MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
202.99MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
73.02MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
145.42MUSDFY2025 · Dec 31, 2025Shares Outstanding
83.61MSharesUpdated Sep 28, 2026Float Shares
55.47MSharesUpdated Sep 28, 2026Shares Short
8.95MSharesUpdated Sep 28, 2026Short Ratio
6.96daysvs all stocks
Short % of Shares Outstanding
14.49%vs all stocks
% Held by Insiders
8.18%vs all stocks
% Held by Institutions
87.78%vs all stocks
Total Cash (MRQ)
537.03MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.31USDUpdated Sep 28, 2026Total Debt (MRQ)
101.53MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2371xvs Biotechnology peers
Current Ratio (MRQ)
12.56xvs Biotechnology peers
Book Value per Share (MRQ)
5.12USDUpdated Sep 28, 2026Total Assets
424.43MUSDvs all stocks (USD)
Total Current Assets
421.69MUSDFY2025 · Dec 31, 2025Total Liabilities
119.95MUSDFY2025 · Dec 31, 2025Total Non-current Assets
2.74MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
74.47MUSDFY2025 · Dec 31, 2025Total Current Liabilities
45.48MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
334.52MUSDFY2025 · Dec 31, 2025Other Short-term Investments
59.45MUSDFY2025 · Dec 31, 2025Accounts Payable
28.43MUSDFY2025 · Dec 31, 2025Short-term Debt
1.23MUSDFY2025 · Dec 31, 2025Long-term Debt
74.47MUSDFY2025 · Dec 31, 2025Common Stock (Book)
7.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-462.91MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
304.48MUSDvs all stocks (USD)
52-Week Low
5.95USDUpdated Sep 28, 202652-Week High
23.29USDUpdated Sep 28, 202652-Week Change
92.79%vs all stocks
Beta
1.03xvs all stocks
50-Day MA
15.94USDUpdated Sep 28, 2026200-Day MA
16.84USDUpdated Sep 28, 2026Avg 10-Day Volume
2.05MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.48MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-3.84USDUpdated Sep 28, 2026Other Income / Expense
22.37MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.61
Altman Z-Score 2.93: safe zoneNotable
Altman Z-Score: 2.93
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Tianjin Tianyao Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Savara Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guangyuyuan Chinese Herbal Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Bide Pharmatech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shantou Institute of Ultrasonic Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dezhan Health Care Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
China Animal Husbandry Industry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alto Neuroscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Aidea Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Qingdao Eastsoft Communication Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline
Sunwoda Electronic Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline
Xianheng International Science And Technology Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline